Table I.
Comparison between groups with regard to age, sex, ALT, HBsAg and HBV DNA levels
| Variable | Treatment group (n = 60) |
END phase (n = 25) |
INC phase (n = 46) |
IC phase (n = 9) |
Value of p |
|---|---|---|---|---|---|
| HBeAg status | (–) | (–) | (–) | (+) | |
| HBsAg levels | 5490 ±7180 | 8360 ±6562 | 2456 ±4055 | 59097 ±55093 | < 0.0001 |
| HBsAg log | 3.43 ±0.59 | 3.79 ±0.41 | 2.78 ±0.84 | 4.50 ±0.59 | < 0.0001 |
| HBV DNA | 13.9 ±44.9 | 0.9 × 107 ±2.5 × 107 | 912 ±1212 | 6.2 × 108 ±7.5 × 108 | < 0.0001 |
| HBV DNA log10 | 1.77 ±0.38 | 5.70 ±1.27 | 2.49 ±0.75 | 8.28 ±0.85 | < 0.0001 |
| HBsAg log/HBV DNA log10 | 1.88 ±0.61 | 0.69 ±0.16 | 1.18 ±0.42 | 0.55 ±0.06 | < 0.0001 |
| Age [year] | 47.8 ±13.0 | 39.3 ±10.8 | 45.3 ±11.4 | 35.3 ±16.1 | 0.004 |
| Gender (female/male) | 24/36 | 13/12 | 24/22 | 5/4 | > 0.05 |
| ALT [IU/ml] | 26.5 ±10.9 | 89 ±123 | 27.6 ±11.2 | 124 ±122 | < 0.0001 |
END phase – HBeAg negative disease phase, INC phase – inactive carrier phase, IC phase – immune clearance phase